brand-logo

Accelagen Staff Announcement – Sahar Bassal

Accelagen Staff Announcement – Sahar Bassal

Sure Clinical

 

One thing that we never lose sight of at Accelagen is that, on the end of every product, every trial, every protocol, every drug — is a patient. And it is our responsibility, and our privilege, to help our innovative global clients to translate ground-breaking science into meaningful gains for these patients all over the world.

Sharing our commitment to patient safety and ‘big picture’ thinking, we would like to formally welcome another experienced team member to Accelagen’s fast-growing Australian team: Sahar Bassal.

Joining the Accelagen team in April 2023, Sahar brings over 15 years’ experience in the pharmaceutical industry and an exemplary academic background to her role as our new Principal Medical Writer.

Medical Writing is a service for which Accelagen is quickly becoming known. From the early clinical phase through to post-marketing, we walk alongside clients to guide them through everything from clinical trial protocols, to investigator brochures, and clinical study reports. In the post-market setting, this also includes supporting pharmacovigilance activities, Regulatory Affairs activities, and anything else required to progress the product along the pipeline from registration to disbursement.

Leading our Medical Writing team, Sahar is driven by a commitment to making sure products are as safe and effective as possible. With a Bachelor of Science (Hons), a Masters in Epidemiology and PhD in biochemistry and cellular biology, Sahar has wide-ranging experience across a variety of disciplines, including early research & development, clinical operations, regulatory affairs, medical affairs, and
pharmacovigilance.

In her role as Principal Medical Writer at Accelagen, Sahar is responsible for managing many high-quality clinical trial projects, covering a vast array of medicine and medical device assets. Providing analysis and medical writing services for both Investigator-led and Sponsor clinical trials, she works closely with Accelagen’s clinical and regulatory teams to interpret quality, non-clinical and clinical data and present it in a clear and concise manner for clients and regulators alike.

Whether it’s writing brochures, clinical protocols or investigational plans for all clinical trial phases, she prides herself on being collaborative and coordinated in her approach, drawing on significant experience in a number of postdoctoral appointments and clinical research roles, including at the US National Institutes of Health, j&j, Celgene, and CSL.

Alongside our team of Medical Writers, Sahar will be in charge of developing crucial documents that ensure full and informed consent, with potential participants provided with a clear and unbiased understanding of the clinical trial, including its purpose, benefits, safety protocols and risk.

It’s already clear that, with her vast expertise and dedication to patient safety, Sahar will play a vital role in helping Accelagen facilitate successful studies that accelerate human health and wellness.

Originally from Egypt, Sahar is incredibly family-focused, and she has two teenage sons and a much-loved dog that keep her on her toes. A passionate advocate not only for women in STEM but in all efforts to empower women and ensure gender equality, now and in the future, she is an asset to the Accelagen team.

Please give Sahar a warm Accelagen welcome!

You might also like...​

You might also like...​

Welcoming our new Business Planning and Analysis Manager

Welcoming our new Business Planning and Analysis Manager   Accelagen is delighted to announce David Stella as our new Business Planning and Analysis Manager. With over a decade of experience in financial planning and analysis, David joins us from IDP Education, an ASX top 100 company, where he excelled in financial reporting and business analysis. […]

Read More
New Appointment Post: Welcoming Cassandra Vung

Accelagen Staff Announcement – Welcoming Cassandra Vung We are thrilled to introduce a recent addition to our Accelagen team, Cassandra Vung. With a strong track record in clinical research, Cassandra joined the team in late April 2023 and has already become an invaluable part of our work, positively impacting the future of human health and […]

Read More
Accelagen Staff Announcement – Sahar Bassal

Accelagen Staff Announcement – Sahar Bassal   One thing that we never lose sight of at Accelagen is that, on the end of every product, every trial, every protocol, every drug — is a patient. And it is our responsibility, and our privilege, to help our innovative global clients to translate ground-breaking science into meaningful […]

Read More